Press Releases

REDWOOD CITY, CA – September 21, 2016 – PaxVax today announced its President and CEO, Nima Farzan, has been invited to join the interim board of the Coalition for Epidemic Preparedness Innovations (CEPI) as the Biotechnology Innovation Organization (BIO) delegate. CEPI is a new, public-private alliance designed to speed the development of new vaccines to prevent and contain global epidemics. Sparked by recent gaps in vaccine preparedness for outbreaks of Zika and Ebola, CEPI aims to facilitate the creation of an arsenal of vaccines to prevent diseases such as these from becoming public health emergencies in the future.

“PaxVax is committed to developing and delivering vaccines that address global public health threats. In joining the CEPI leadership, I look forward to continue pursuing innovative efforts aimed to prepare against future pandemics,” said Farzan. “As biotech companies have both the expertise and responsibility to take part in this cause, I am thrilled to join CEPI’s visionary team of experts in the global fight to protect against infectious diseases.”

CEPI was founded by the Wellcome Trust, the Bill and Melinda Gates Foundation, the World Economic Forum and the governments of Norway and India. The organization will finance, coordinate and facilitate the development of vaccines for potential global threats before outbreaks begin. Farzan joins CEPI’s board of global leaders from academia, government, non-profits and industry, gathered to shape an informed, collaborative approach to ensure vaccines are available for all populations who need them.

 

“We have seen in recent outbreaks that when working alone, industry players face barriers to vaccine development,” Farzan said. “CEPI’s collaborative approach is vital in taking on global health threats. I am proud to serve on its board among leaders forging a unified response to pandemics.”

Farzan has been President and CEO of PaxVax since 2015 and previously served as Chief Operating Officer from 2011. He has extensive biopharmaceutical experience, most recently providing leadership at PaxVax in the advancement of a vaccine for cholera from research and development through to approval by the U.S. Food and Drug Administration.

About PaxVax

PaxVax develops, manufactures and commercializes innovative specialty vaccines against infectious diseases present and emerging in the developing world. PaxVax has licensed vaccines for typhoid fever (Vivotif®) and cholera (Vaxchora), and vaccines at various stages of research and clinical development for adenovirus, anthrax, hepatitis A, HIV, and Zika. PaxVax is focused on traditionally overlooked markets such as travel, and as part of its social mission, PaxVax is also working to make its vaccines available to broader populations most affected by these diseases. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California and Bern, Switzerland and other operations in Bermuda and Europe. More information is available at www.PaxVax.com.

Contact

David Polk

Biosector 2

310-309-1029

 

David.Polk@inventivhealth.com 

Specialty Vaccine Company PaxVax Secures Up to $60 Million in Financing

Proceeds to Support New European Operations and Clinical Development, Regulatory Review and Anticipated Global Launch of Late-Stage Cholera Vaccine Candidate

REDWOOD CITY, Calif. – July 28, 2014 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that it has closed up to $50 million in secured debt financing from an investment fund managed by Pharmakon Advisors and $12 million in an extension on its Series B preferred stock. This financing was secured as part of the company’s acquisition of the FDA-approved oral typhoid vaccine Vivotif® from Crucell Switzerland AG, also announced today. Additional proceeds from this financing will be used to support clinical development, regulatory review and the expected global launch of PaxVax’s cholera vaccine candidate, PXVX0200, currently in Phase 3 clinical testing.

PaxVax Acquires the FDA-Approved Typhoid Vaccine Vivotif

Deal Also Includes Manufacturing and Development Facility in Switzerland

REDWOOD CITY, Calif. -- July 28, 2014 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG, as well as its manufacturing facility in Thörishaus, near Bern, Switzerland. Additionally, PaxVax is acquiring marketing, sales and distribution capabilities in select markets including the United States, and certain other assets related to travel vaccines such as hepatitis A. Financial terms of the transaction were not disclosed.

Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study

New Efficacy Data Adds to Successful Phase 3 Clinical Trial Program Results for Single-Dose Oral Cholera Vaccine for Travelers' Market and People in the Developing World

REDWOOD CITY, Calif. – July 1, 2014 – PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced positive efficacy results from the 90-day challenge studies of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain (CVD 103-HgR) previously approved and marketed in several countries under the brand name Orochol. Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo.

PaxVax Signs R&D Collaboration with UC San Diego to Develop a Vaccine to Prevent Herpes Simplex Virus Infections

Redwood City and San Diego, Calif., -- June 10, 2014 -- PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections.

Specialty Vaccine Company PaxVax to Present at the Jefferies 2014 Global Healthcare Conference

REDWOOD CITY, Calif. – May 27, 2014 – PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that company Chief Executive Officer Ken Kelley will present at the Jefferies 2014 Global Healthcare Conference in New York City on Tuesday, June 3 at 10:00 a.m. EDT. A breakout session will follow at 10:30 a.m. EDT.

Specialty Vaccine Company PaxVax Selected to Present at Cavendish Global Health Impact Forum

Redwood City, May 1, 2014 -- PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure global access to its vaccines, today announced that company Chief Executive Officer Ken Kelley will present at the Cavendish Global Health Impact Forum taking place at the United Nations Headquarters and Rockefeller University in New York City, May 5-7, 2014.

Specialty Vaccine Company PaxVax Appoints Jim Connolly to Board of Directors

Industry Veteran Joins Company as it Readies for the Anticipated Commercial Launch of its Cholera Vaccine for Travelers

Redwood City – APRIL 29, 2014 – PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure global access to its vaccines, today announced the appointment of Jim Connolly to its Board of Directors. Connolly joins current Board members Rennie Coit, M.D., and Rich Tong from Ignition Capital; retired Major General Philip K. Russell, M.D.; Howie Rosen; and PaxVax Chief Executive Officer Kenneth Kelley.

PaxVax to Present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

Presentation and Webcast Held Friday, March 28 at 9:30 a.m. Eastern Time

MENLO PARK and SAN DIEGO – MARCH 25, 2014 – PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure global access to its vaccines, today announced that Kenneth Kelley, Chief Executive Officer of PaxVax, will present at the BioCentury Future Leaders in the Biotech Industry Conference in New York. Mr. Kelley’s presentation is scheduled for 9:30 a.m. EDT on Friday, March 28th in Presentation Room 402/403 at the Millennium Broadway Hotel & Conference Center. A Breakout Session will follow from 10:00 – 10:30 a.m. EDT in Breakout Room 401.

PaxVax Announces New Commercial Senior Leadership Appointments

New Hires Expand Senior Management Team Ahead of Anticipated Cholera Vaccine Launch

MENLO PARK and SAN DIEGO – MARCH 3, 2014 – PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure global access to its vaccines, today announced the expansion of its commercial leadership team, including appointments of: Linda Rubinstein as Chief Financial Officer; Piers Whitehead as Chief Corporate Development Officer; and Thomas Yonker as Vice President of Project Management.

PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned

Double-Bottom Line Company Intends to Bring Single-Dose Oral Cholera Vaccine to Travelers' Market First, Then to Developing World

Menlo Park, Calif., – January 9, 2014 – PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced interim data from a Phase 3 cholera challenge study of its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo. The vaccine appeared well tolerated. In an interim analysis of participants challenged at 10 days post vaccination with wild type, fully pathogenic cholera bacteria the rate of diarrhea was reduced in the vaccine group: 20 of 33 participants who received placebo experienced moderate-to-severe diarrhea compared to two of 35 participants who received PXVX0200.

Pages